Achieving Containment in High-Potency Manufacturing: A Case Study for Solid Dosage Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Achieving Containment in High-Potency Manufacturing: A Case Study for Solid Dosage Manufacturing
A Q&A with Joe Cascone, director of potent pharmaceutical development at Metrics, moderated by Patricia Van Arnum. Discussion of the key considerations made in facility design, equipment selection, and operations to achieve desired levels of containment.

Pharmaceutical Technology
Volume 35, pp. s34-s35

PharmTech: A key challenge in high-potency manufacturing is to maintain the level of containment throughout the manufacturing process. Before examining how that is achieved operationally, what are the key considerations when designing a high-potency manufacturing facility and in equipment selection?

Interior of the multiuse isolator with a high-shear granulator, conical mill, and roller compactor installed. (IMAGE IS COURTESY OF METRICS)
Cascone: The concept of risk management was a major element of the facility design discussion at Metrics. The team (consisting of director-level managers from pharmaceutical development, environmental, health and safety, quality assurance, and operations as well as personnel from external engineering firms) considered the risks associated with locating a high-potency solid-oral dosage form facility adjacent to one designed for compounds with occupational exposure limits greater than 10 μg/m3 time weighted average. These risks were placed into two major categories. The first were risks associated with protecting the employee. The second were risks associated with protecting the drug product(s).

To manage the risks of operator exposure, the team adopted the following tenets:

  • Operators will not work with an unclassified compound.
  • Operators will not work with a compound that cannot be suitably contained.
  • The containment capabilities of equipment will be tested and quantified.
  • Secondary protection will be available in the event of a containment breach.
  • Engineered solutions (i.e., hard-wall isolators) were preferred to work-practice solutions (i.e., laminar-flow enclosures).
  • Operators will be monitored for adverse health effects.

To manage the risks of a cross-contamination event, the team established the following requirements:
  • Potent compounds will be processed under hard-wall isolation.
  • Potent compounds would be processed in rooms discrete from other GMP manufacturing areas.
  • Operators will not transit one GMP area to access another GMP area in which potent compounds are processed. Multiple airlocks (i.e., gray areas) will separate rooms in which potent compounds are processed from surrounding areas.
  • Air handling and utilities will be separate; room pressurization will be such that dust is contained.
  • Equipment used in the manufacture of potent products will not be used outside the potent facility.
  • Equipment will be chemically tested for cleanliness by high-performance liquid chromatography and total organic carbon analysis after each processing event.
  • Disposable accoutrements will be used where feasible.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here